Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.

Saved in:
Bibliographic Details
Title: Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
Authors: Rahma OE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Reuss JE; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Giobbie-Hurder A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts., Shoja E Razavi G; Cumming School of Medicine, University of Calgary, Calgary, Canada., Abu-Shawer O; Harvard Medical School, Boston, Massachusetts., Mehra P; University of Virginia, Charlottesville, Virginia., Gupta S; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Simon R; R Simon Consulting, Potomac, Maryland., Khleif SN; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. snk48@georgetown.edu.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jan 15; Vol. 27 (2), pp. 485-491. Date of Electronic Publication: 2020 Oct 20.
Publication Type: Journal Article; Meta-Analysis
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-20-2669